Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals Inc. (ACAD)
:ACAD
ACAD Stock Chart & Stats
$21.39
-$0.09(-0.52%)
At close: 4:00 PM EST
$21.39
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$13.40 - $26.65
Previous CloseN/A
Volume443.16K
Average Volume (3M)2.38M
Market Cap
$3.53B
Enterprise Value$2.93B
Total Cash (Recent Filing)$762.00M
Total Debt (Recent Filing)$44.60M
Price to Earnings (P/E)16.0
Beta1.19
Next Earnings
Nov 05, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding168,712,220
10 Day Avg. Volume2,338,118
30 Day Avg. Volume2,378,625
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda27.59
Forecast
1Y Price Target
$29.61Price Target Upside38.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Financial StabilityACAD had ~$762 million in cash at the end of 2Q25, with no imminent need to raise capital, highlighting financial stability.
Patent ExtensionThe market is over-penalizing Nuplazid sales despite resolved patent litigation, which extends the patent into 2038.
Product ExpansionDaybue should continue to ramp in the US and internationally, with expansion plans in Japan and possible approval in the EU.
Bears Say
Product Development FailureThe stock dropped approximately 10% following the failure of ACP-101 in Prader-Willi Syndrome.
Undervalued PipelineAcadia's pipeline is not adequately reflected in the stock today, and value appreciation is expected upon future readouts.
Unrealized Pipeline ValueInvestors seem to be assigning little-to-no value to earlier-stage assets ACP-211 in major depressive disorder and ACP-711 in essential tremor, while credit is given to these programs on a risk-adjusted basis.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals Inc.’s price range in the past 12 months?
ACADIA Pharmaceuticals Inc. lowest stock price was $13.40 and its highest was $26.65 in the past 12 months.
What is ACADIA Pharmaceuticals Inc.’s market cap?
ACADIA Pharmaceuticals Inc.’s market cap is $3.53B.
When is ACADIA Pharmaceuticals Inc.’s upcoming earnings report date?
ACADIA Pharmaceuticals Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 13 days.
How were ACADIA Pharmaceuticals Inc.’s earnings last quarter?
ACADIA Pharmaceuticals Inc. released its earnings results on Aug 06, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.138 by $0.022.
Is ACADIA Pharmaceuticals Inc. overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals Inc.’s price is currently Undervalued.
Does ACADIA Pharmaceuticals Inc. pay dividends?
ACADIA Pharmaceuticals Inc. does not currently pay dividends.
What is ACADIA Pharmaceuticals Inc.’s EPS estimate?
ACADIA Pharmaceuticals Inc.’s EPS estimate is 0.14.
How many shares outstanding does ACADIA Pharmaceuticals Inc. have?
ACADIA Pharmaceuticals Inc. has 168,712,220 shares outstanding.
What happened to ACADIA Pharmaceuticals Inc.’s price movement after its last earnings report?
ACADIA Pharmaceuticals Inc. reported an EPS of $0.16 in its last earnings report, beating expectations of $0.138. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in ACAD
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.61 (38.43% Upside)
$29.61 (38.43% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 444.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $41.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.31%
12-Months-Change
Fundamentals
Return on Equity
33.18%
Trailing 12-Months
Asset Growth
34.07%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with strong financial performance, significant growth in DAYBUE and NUPLAZID sales, and a robust pipeline expansion. However, increased SG&A expenses and challenges in clinical trials were noted as areas of concern.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$29.61
▲(38.43% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
23.64% Insiders
15.71% Mutual Funds
0.02% Other Institutional Investors
35.56% Public Companies and Individual Investors